September 2015 Analysis

Industry Trend Analysis - Biosimilars Will Be Essential In Future RA Treatment Options - SEPT 2015

The presentation of trial data for biosimilars reflects the growing shape and size of the biosimilar market for autoimmune products, particularly in Europe. The conference has also recognised that the increasing prevalence of biosimilars is leading to questions and anxiety amongst patients, a concern that can also be discerned in Hospira's biosimilar infliximab presentation. Tackling these...